A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer

The goal of this clinical trial is to learn if the investigational drug BL0175 works to treat adult postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative locally advanced or metastatic breast cancer, ovarian cancer and endometrial cancer. It will also learn about the safety of BL0175. The main questions it aims to answer are: * Does the investigational drug BL0175 is safe for participants after dosed -multiple times? * Which is the highest safety dose of BL0175 after multiple dose? * What medical problems do participants have when usi

Trial Details

NCT ID
NCT06738966
Phase
PHASE1
Sponsor
Shanghai Best-Link Bioscience, LLC
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • BL0175
Locations (sample)
  • Changchun, Jilin, China|43.88,125.32278
  • Jinan, Shandong, China|36.66833,116.99722

Key Eligibility Criteria

  • Volunteer to participate in the study, be able to understand the requirements of a clinical study, and willingness to sign a written informed conse…
  • Age ≥ 18 years.
  • HR-positive, HER2-negative (characterized by the absence of HER2 expression and the presence of ER and/or PR expression) locally advanced or metast…
  • Patients with at least one measurable or evaluable lesion: At least one lesion (measurable and/or non-measurable) that can be accurately assessed b…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →